PMID- 32016480
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20210922
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 21
IP  - 3
DP  - 2020 Mar
TI  - Anti‑metastatic effects of arctigenin are regulated by MAPK/AP‑1 signaling in 
      4T‑1 mouse breast cancer cells.
PG  - 1374-1382
LID - 10.3892/mmr.2020.10937 [doi]
AB  - Arctigenin is a natural lignan that is found in burdock with anti‑viral, 
      ‑oxidative, ‑inflammatory and anti‑tumor activities. In the current study, the 
      effect of arctigenin on metastatic potential was examined in 4T‑1 mouse 
      triple‑negative breast cancer cells. The results indicated that arctigenin 
      inhibited cell motility and invasiveness, which was determined using wound 
      healing and transwell invasion assays. Arctigenin suppressed matrix 
      metalloprotease‑9 (MMP‑9) activity via gelatin zymography, and protein expression 
      of cyclooxygenase‑2 (COX‑2) and MMP‑3. Furthermore, arctigenin attenuated the 
      mRNA expression of metastatic factors, including MMP‑9, MMP‑3 and COX‑2. Based on 
      these results, the effect of arctigenin on the mitogen‑activated protein kinase 
      (MAPK)/activating protein‑1 (AP‑1) signaling pathway was assessed in an attempt 
      to identify the regulatory mechanism responsible for its anti‑metastatic effects. 
      Arctigenin was demonstrated to inhibit the phosphorylation of extracellular 
      signal‑regulated protein kinase (ERK) and c‑Jun N‑terminal kinase (JNK), and the 
      nuclear translocations of the AP‑1 subunits, c‑Jun and c‑Fos. In summary, the 
      present study demonstrated that in 4T‑1 mouse triple‑negative breast cancer cells 
      the anti‑metastatic effect of arctigenin is mediated by the inhibition of MMP‑9 
      activity and by the inhibition of the metastasis‑enhancing factors MMP‑9, MMP‑3 
      and COX‑2, due to the suppression of the MAPK/AP‑1 signaling pathway. The results 
      of the current study demonstrated that arctigenin exhibits a potential for 
      preventing cell migration and invasion in triple negative breast cancer.
FAU - Lee, Min-Gu
AU  - Lee MG
AD  - Department of Pharmacology and Intractable Disease Research Center, School of 
      Medicine, Dongguk University, Gyeongju 38066, Republic of Korea.
FAU - Lee, Kyu-Shik
AU  - Lee KS
AD  - Department of Pharmacology and Intractable Disease Research Center, School of 
      Medicine, Dongguk University, Gyeongju 38066, Republic of Korea.
FAU - Nam, Kyung-Soo
AU  - Nam KS
AD  - Department of Pharmacology and Intractable Disease Research Center, School of 
      Medicine, Dongguk University, Gyeongju 38066, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20200113
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Furans)
RN  - 0 (Lignans)
RN  - 0 (Matrix Metalloproteinase Inhibitors)
RN  - 0 (Transcription Factor AP-1)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - U76MR9VS6M (arctigenin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents, Phytogenic/*pharmacology
MH  - Arctium/*chemistry
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Female
MH  - Furans/*pharmacology
MH  - Humans
MH  - Lignans/*pharmacology
MH  - *MAP Kinase Signaling System
MH  - Matrix Metalloproteinase 9/genetics/metabolism
MH  - Matrix Metalloproteinase Inhibitors/*pharmacology
MH  - Mice
MH  - Neoplasm Invasiveness
MH  - Phosphorylation/drug effects
MH  - Signal Transduction/drug effects
MH  - Transcription Factor AP-1/*metabolism
MH  - Triple Negative Breast Neoplasms/*drug therapy
OTO - NOTNLM
OT  - arctigenin
OT  - triple-negative breast cancer
OT  - metastatic potential
OT  - matrix metalloprotease-9
OT  - activating protein-1
EDAT- 2020/02/06 06:00
MHDA- 2020/10/21 06:00
CRDT- 2020/02/05 06:00
PHST- 2019/07/23 00:00 [received]
PHST- 2019/10/29 00:00 [accepted]
PHST- 2020/02/06 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/02/05 06:00 [entrez]
AID - 10.3892/mmr.2020.10937 [doi]
PST - ppublish
SO  - Mol Med Rep. 2020 Mar;21(3):1374-1382. doi: 10.3892/mmr.2020.10937. Epub 2020 Jan 
      13.